Atea Pharmaceuticals, Inc.
General ticker "AVIR" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $268.2M (TTM average)
Atea Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 32.1%.
Estimated limits based on current volatility of 1.2%: low 3.02$, high 3.10$
Factors to consider:
- Total employees count: 56 (-25.3%) as of 2024
- Top business risk factors: Substantial financing needs, Single product reliance, High operating expenses, Manufacturing risks, Intellectual property risks
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.01$, 5.05$]
- 2025-12-31 to 2026-12-31 estimated range: [1.57$, 4.08$]
Financial Metrics affecting the AVIR estimates:
- Positive: with PPE of -1.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -49.44 <= 0.33
- Positive: Shareholder equity ratio, % of 94.45 > 63.39
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
Short-term AVIR quotes
Long-term AVIR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $130.65MM | $164.16MM | $192.95MM |
| Operating Income | $-130.65MM | $-164.16MM | $-192.95MM |
| Non-Operating Income | $11.15MM | $29.22MM | $25.49MM |
| R&D Expense | $81.94MM | $114.24MM | $144.10MM |
| Income(Loss) | $-119.50MM | $-134.94MM | $-167.46MM |
| Taxes | $-3.59MM | $1.02MM | $0.93MM |
| Profit(Loss)* | $-115.91MM | $-135.96MM | $-168.38MM |
| Stockholders Equity | $640.57MM | $555.19MM | $438.87MM |
| Assets | $666.71MM | $594.97MM | $464.67MM |
| Operating Cash Flow | $-120.98MM | $-85.39MM | $-135.50MM |
| Capital expenditure | $1.94MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-455.41MM | $40.30MM | $56.10MM |
| Financing Cash Flow | $0.37MM | $0.26MM | $0.27MM |
| Earnings Per Share** | $-1.39 | $-1.63 | $-2.00 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.